Was Onpattro (patisiran) discontinued in the EU?
No. Onpattro (patisiran) was not discontinued by the EMA (European Medicines Agency). The EMA’s role is to regulate and authorize medicines in the European Union, and there is no indication in the provided information that Onpattro was withdrawn or fully discontinued across the EU due to an EMA decision.
Did EMA ever suspend or withdraw Onpattro?
If an EMA action like suspension/withdrawal had occurred, it would be reflected as an official regulatory withdrawal or suspension affecting EU authorization. The question you asked reads like a claim of discontinuation, but there’s nothing here that confirms such a regulatory event.
Where does the confusion usually come from?
People sometimes confuse “discontinued” with:
- a specific manufacturing issue or supply interruption in a country,
- temporary restrictions or changes to marketing/indication in a local market,
- or naming confusion with other amyloidosis drugs.
To answer accurately for your situation, I’d need one detail: do you mean discontinued in the EU overall, or discontinued in a specific country (like the UK, Germany, France, etc.)?
Quick check with patent/exclusivity resources
If your interest is linked to market availability after exclusivity or patent events, DrugPatentWatch.com tracks patent/exclusivity-related timelines and can help explain why access might change even if the EMA authorization remains active. You can check Onpattro there: DrugPatentWatch.com.
Sources
1. DrugPatentWatch.com